---
document_datetime: 2025-12-02 05:22:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nordimet.html
document_name: nordimet.html
version: success
processing_time: 0.1538348
conversion_datetime: 2025-12-28 09:47:56.084157
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nordimet

[RSS](/en/individual-human-medicine.xml/66296)

##### Authorised

This medicine is authorised for use in the European Union

methotrexate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nordimet](#news-on)
- [Related information](#related-information-656)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78079)
- [More information on Nordimet](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Nordimet is a medicine used to treat the following inflammatory conditions:

- active rheumatoid arthritis, a disease causing inflammation in joints;
- severe juvenile idiopathic arthritis (JIA), a joint disease in children, when medicines known as NSAIDs (non-steroidal anti-inflammatory drugs) have not worked well enough;
- plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease who can be treated with a medicine given by mouth or injection;
- severe psoriatic arthritis, inflammation of the joints that occurs in patients with psoriasis;
- Crohn's disease (a disease causing inflammation of the gut) in adults. It can be used in combination with corticosteroids or on its own to induce or maintain remission (a period without disease symptoms after treatment).

Nordimet contains the active substance methotrexate.

Nordimet is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, but Nordimet is available in more strengths. The reference medicine for Nordimet is Lantarel FS.

Expand section

Collapse section

## How is Nordimet used?

Nordimet is available in pre-filled injection pens or syringes and it can only be obtained with a prescription. It should be prescribed only by doctors with expertise in the use of methotrexate and a full understanding of the risks of methotrexate treatment.

Nordimet should be injected under the skin once a week on the same day each week. The dose injected each week depends on which condition it is being used for and how well the treatment is working and, for children, on the child's height and weight. In most cases, methotrexate medicines are used for long-term treatment.

A doctor may decide that patients can inject Nordimet themselves after receiving adequate training, but the first self-injection should be supervised by a doctor or a nurse.

For more information about using Nordimet, see the package leaflet or contact your doctor or pharmacist.

## How does Nordimet work?

The way methotrexate, the active substance in Nordimet, works in patients with arthritis, psoriasis and Crohn's disease is not completely understood, but the benefits of methotrexate are thought to be due to its ability to reduce inflammation and suppress an overactive immune system.

## What benefits of Nordimet have been shown in studies?

The company provided data from the published literature on methotrexate. No additional studies were needed as Nordimet is a hybrid medicine that is given by injection and contains the same active substance as the reference medicine, Lantarel FS. Because Nordimet has the same composition as the reference medicine its benefits are taken as being the same as those of Lantarel FS.

## What are the risks associated with Nordimet?

For the full list of side effects and restrictions of Nordimet, see the package leaflet.

The most common side effects with Nordimet (which may affect more than 1 in 10 people) include effects on the digestive system (such as inflammation of the lining of the mouth, indigestion, belly pain, feeling sick and loss of appetite) and blood tests showing changes in how well the liver works. The most serious side effects include reduced production of blood cells, damage to the lungs, liver, kidneys and nerves, thromboembolism (problems caused by clots in blood vessels), severe allergic reactions and Stevens-Johnson syndrome (life-threatening reaction with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals).

Nordimet must not be used in patients who abuse alcohol or those with severe liver or kidney problems, blood disorders, weakened immune system (the body's natural defences), severe or long-term infections such as tuberculosis and HIV infection, mouth ulcers, inflammation of the lining of the mouth, and ulcers in the digestive system. It must not be used if the patient is pregnant, breastfeeding or is receiving live vaccines.

## Why is Nordimet authorised in the EU?

The European Medicines Agency concluded that Nordimet was comparable to its reference medicine. The Agency therefore decided that Nordimet's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Nordimet?

The company that markets Nordimet will send out follow-up questionnaires for dosing errors that result in overdose.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nordimet have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Nordimet are continuously monitored. Side effects reported with Nordimet are carefully evaluated and any necessary action taken to protect patients.

## Other information about Nordimet

Nordimet received a marketing authorisation valid throughout the EU on 18 August 2016.

Nordimet : EPAR - Medicine overview

Reference Number: EMA/480738/2023

English (EN) (146.5 KB - PDF)

**First published:** 29/09/2016

**Last updated:** 20/11/2023

[View](/en/documents/overview/nordimet-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-92)

български (BG) (131.51 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/bg/documents/overview/nordimet-epar-medicine-overview_bg.pdf)

español (ES) (107.61 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/es/documents/overview/nordimet-epar-medicine-overview_es.pdf)

čeština (CS) (127.33 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/cs/documents/overview/nordimet-epar-medicine-overview_cs.pdf)

dansk (DA) (106.88 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/da/documents/overview/nordimet-epar-medicine-overview_da.pdf)

Deutsch (DE) (107.96 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/de/documents/overview/nordimet-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.36 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/et/documents/overview/nordimet-epar-medicine-overview_et.pdf)

ελληνικά (EL) (139.4 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/el/documents/overview/nordimet-epar-medicine-overview_el.pdf)

français (FR) (108.07 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/fr/documents/overview/nordimet-epar-medicine-overview_fr.pdf)

hrvatski (HR) (121.39 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/hr/documents/overview/nordimet-epar-medicine-overview_hr.pdf)

italiano (IT) (107.27 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/it/documents/overview/nordimet-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (135.05 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/lv/documents/overview/nordimet-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (125.82 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/lt/documents/overview/nordimet-epar-medicine-overview_lt.pdf)

magyar (HU) (122.23 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/hu/documents/overview/nordimet-epar-medicine-overview_hu.pdf)

Malti (MT) (127.16 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/mt/documents/overview/nordimet-epar-medicine-overview_mt.pdf)

Nederlands (NL) (107.54 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/nl/documents/overview/nordimet-epar-medicine-overview_nl.pdf)

polski (PL) (126.73 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/pl/documents/overview/nordimet-epar-medicine-overview_pl.pdf)

português (PT) (107.44 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/pt/documents/overview/nordimet-epar-medicine-overview_pt.pdf)

română (RO) (123.86 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/ro/documents/overview/nordimet-epar-medicine-overview_ro.pdf)

slovenčina (SK) (125.68 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/sk/documents/overview/nordimet-epar-medicine-overview_sk.pdf)

slovenščina (SL) (120.89 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/sl/documents/overview/nordimet-epar-medicine-overview_sl.pdf)

Suomi (FI) (106.91 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/fi/documents/overview/nordimet-epar-medicine-overview_fi.pdf)

svenska (SV) (106.7 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

20/11/2023

[View](/sv/documents/overview/nordimet-epar-medicine-overview_sv.pdf)

Nordimet : EPAR - Risk-management-plan summary

English (EN) (118.54 KB - PDF)

**First published:** 02/02/2021

**Last updated:** 27/10/2023

[View](/en/documents/rmp-summary/nordimet-epar-risk-management-plan-summary_en.pdf)

## Product information

Nordimet : EPAR - Product Information

English (EN) (1.14 MB - PDF)

**First published:** 29/09/2016

**Last updated:** 17/07/2025

[View](/en/documents/product-information/nordimet-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-125)

български (BG) (1.41 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/bg/documents/product-information/nordimet-epar-product-information_bg.pdf)

español (ES) (1.1 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/es/documents/product-information/nordimet-epar-product-information_es.pdf)

čeština (CS) (1.29 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/cs/documents/product-information/nordimet-epar-product-information_cs.pdf)

dansk (DA) (1.06 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/da/documents/product-information/nordimet-epar-product-information_da.pdf)

Deutsch (DE) (1.14 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/de/documents/product-information/nordimet-epar-product-information_de.pdf)

eesti keel (ET) (1.11 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/et/documents/product-information/nordimet-epar-product-information_et.pdf)

ελληνικά (EL) (1.36 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/el/documents/product-information/nordimet-epar-product-information_el.pdf)

français (FR) (1.12 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/fr/documents/product-information/nordimet-epar-product-information_fr.pdf)

hrvatski (HR) (1.32 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/hr/documents/product-information/nordimet-epar-product-information_hr.pdf)

íslenska (IS) (1.13 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/is/documents/product-information/nordimet-epar-product-information_is.pdf)

italiano (IT) (1.14 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/it/documents/product-information/nordimet-epar-product-information_it.pdf)

latviešu valoda (LV) (1.36 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/lv/documents/product-information/nordimet-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.28 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/lt/documents/product-information/nordimet-epar-product-information_lt.pdf)

magyar (HU) (1.23 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/hu/documents/product-information/nordimet-epar-product-information_hu.pdf)

Malti (MT) (1.37 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/mt/documents/product-information/nordimet-epar-product-information_mt.pdf)

Nederlands (NL) (1.12 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/nl/documents/product-information/nordimet-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/no/documents/product-information/nordimet-epar-product-information_no.pdf)

polski (PL) (1.32 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/pl/documents/product-information/nordimet-epar-product-information_pl.pdf)

português (PT) (1.15 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/pt/documents/product-information/nordimet-epar-product-information_pt.pdf)

română (RO) (1.38 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/ro/documents/product-information/nordimet-epar-product-information_ro.pdf)

slovenčina (SK) (1.39 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/sk/documents/product-information/nordimet-epar-product-information_sk.pdf)

slovenščina (SL) (1.34 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/sl/documents/product-information/nordimet-epar-product-information_sl.pdf)

Suomi (FI) (1.18 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/fi/documents/product-information/nordimet-epar-product-information_fi.pdf)

svenska (SV) (1.11 MB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/sv/documents/product-information/nordimet-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000282579 15/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nordimet : EPAR - All Authorised presentations

English (EN) (124.52 KB - PDF)

**First published:** 29/09/2016

**Last updated:** 17/07/2025

[View](/en/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-515)

български (BG) (199.13 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/bg/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_bg.pdf)

español (ES) (163.7 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/es/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_es.pdf)

čeština (CS) (161.14 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/cs/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (132.14 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/da/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (138.24 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/de/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (126.25 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/et/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (171.93 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/el/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_el.pdf)

français (FR) (135.71 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/fr/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (150.84 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/hr/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (157.37 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/is/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_is.pdf)

italiano (IT) (127.63 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/it/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (156.77 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/lv/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (152.28 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/lt/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (165.77 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/hu/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (169.32 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/mt/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (129.7 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/nl/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (134.64 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/no/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_no.pdf)

polski (PL) (197.19 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/pl/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_pl.pdf)

português (PT) (132.38 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/pt/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_pt.pdf)

română (RO) (161.77 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/ro/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (156.41 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/sk/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (166.43 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/sl/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (158.17 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/fi/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (156.61 KB - PDF)

**First published:**

29/09/2016

**Last updated:**

17/07/2025

[View](/sv/documents/all-authorised-presentations/nordimet-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nordimet Active substance methotrexate International non-proprietary name (INN) or common name methotrexate Therapeutic area (MeSH)

- Arthritis, Psoriatic
- Psoriasis
- Arthritis, Juvenile Rheumatoid
- Arthritis, Rheumatoid

Anatomical therapeutic chemical (ATC) code L04AX03

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Nordimet is indicated for the treatment of:

- active rheumatoid arthritis in adult patients,
- polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,
- moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients,
- induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.

## Authorisation details

EMA product number EMEA/H/C/003983 Marketing authorisation holder

Nordic Group B.V.

Siriusdreef 41

Opinion adopted 23/06/2016 Marketing authorisation issued 18/08/2016 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nordimet : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (185.46 KB - PDF)

**First published:** 17/07/2025

[View](/en/documents/procedural-steps-after/nordimet-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Methotrexate Article-31 referral - Annex II

English (EN) (48.08 KB - PDF)

**First published:** 31/10/2019

[View](/en/documents/referral/methotrexate-article-31-referral-annex-ii_en.pdf)

[Other languages (22)](#file-language-dropdown-566)

български (BG) (70.65 KB - PDF)

**First published:**

31/10/2019

[View](/bg/documents/referral/methotrexate-article-31-referral-annex-ii_bg.pdf)

español (ES) (52.71 KB - PDF)

**First published:**

31/10/2019

[View](/es/documents/referral/methotrexate-article-31-referral-annex-ii_es.pdf)

čeština (CS) (96.45 KB - PDF)

**First published:**

31/10/2019

[View](/cs/documents/referral/methotrexate-article-31-referral-annex-ii_cs.pdf)

dansk (DA) (48.48 KB - PDF)

**First published:**

31/10/2019

[View](/da/documents/referral/methotrexate-article-31-referral-annex-ii_da.pdf)

Deutsch (DE) (110.91 KB - PDF)

**First published:**

31/10/2019

[View](/de/documents/referral/methotrexate-article-31-referral-annex-ii_de.pdf)

eesti keel (ET) (48.23 KB - PDF)

**First published:**

31/10/2019

[View](/et/documents/referral/methotrexate-article-31-referral-annex-ii_et.pdf)

ελληνικά (EL) (101.99 KB - PDF)

**First published:**

31/10/2019

[View](/el/documents/referral/methotrexate-article-31-referral-annex-ii_el.pdf)

français (FR) (52.78 KB - PDF)

**First published:**

31/10/2019

[View](/fr/documents/referral/methotrexate-article-31-referral-annex-ii_fr.pdf)

hrvatski (HR) (88.18 KB - PDF)

**First published:**

31/10/2019

[View](/hr/documents/referral/methotrexate-article-31-referral-annex-ii_hr.pdf)

italiano (IT) (49.13 KB - PDF)

**First published:**

31/10/2019

[View](/it/documents/referral/methotrexate-article-31-referral-annex-ii_it.pdf)

latviešu valoda (LV) (91.68 KB - PDF)

**First published:**

31/10/2019

[View](/lv/documents/referral/methotrexate-article-31-referral-annex-ii_lv.pdf)

lietuvių kalba (LT) (98.34 KB - PDF)

**First published:**

31/10/2019

[View](/lt/documents/referral/methotrexate-article-31-referral-annex-ii_lt.pdf)

magyar (HU) (81.89 KB - PDF)

**First published:**

31/10/2019

[View](/hu/documents/referral/methotrexate-article-31-referral-annex-ii_hu.pdf)

Malti (MT) (105.98 KB - PDF)

**First published:**

31/10/2019

[View](/mt/documents/referral/methotrexate-article-31-referral-annex-ii_mt.pdf)

Nederlands (NL) (50.84 KB - PDF)

**First published:**

31/10/2019

[View](/nl/documents/referral/methotrexate-article-31-referral-annex-ii_nl.pdf)

polski (PL) (95.12 KB - PDF)

**First published:**

31/10/2019

[View](/pl/documents/referral/methotrexate-article-31-referral-annex-ii_pl.pdf)

português (PT) (51.81 KB - PDF)

**First published:**

31/10/2019

[View](/pt/documents/referral/methotrexate-article-31-referral-annex-ii_pt.pdf)

română (RO) (92.88 KB - PDF)

**First published:**

31/10/2019

[View](/ro/documents/referral/methotrexate-article-31-referral-annex-ii_ro.pdf)

slovenčina (SK) (91.73 KB - PDF)

**First published:**

31/10/2019

[View](/sk/documents/referral/methotrexate-article-31-referral-annex-ii_sk.pdf)

slovenščina (SL) (87.25 KB - PDF)

**First published:**

31/10/2019

[View](/sl/documents/referral/methotrexate-article-31-referral-annex-ii_sl.pdf)

Suomi (FI) (49.34 KB - PDF)

**First published:**

31/10/2019

[View](/fi/documents/referral/methotrexate-article-31-referral-annex-ii_fi.pdf)

svenska (SV) (50.58 KB - PDF)

**First published:**

31/10/2019

[View](/sv/documents/referral/methotrexate-article-31-referral-annex-ii_sv.pdf)

Methotrexate Article-31 referral - Public assessment report - EMEA/H/A-31/1463

Reference Number: EMA/521627/2019

English (EN) (323.24 KB - PDF)

**First published:** 31/10/2019

[View](/en/documents/referral/methotrexate-article-31-referral-public-assessment-report-emeaha-311463_en.pdf)

Nordimet : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (123.57 KB - PDF)

**First published:** 21/10/2016

**Last updated:** 17/07/2025

[View](/en/documents/procedural-steps-after/nordimet-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Nordimet-H-C-PSUSA-00002014-202310 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/410704/2024

English (EN) (93.3 KB - PDF)

**First published:** 05/09/2024

[View](/en/documents/scientific-conclusion/nordimet-h-c-psusa-00002014-202310-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Nordimet-H-C-3983-II-0027 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/439575/2023

English (EN) (1.82 MB - PDF)

**First published:** 27/10/2023

[View](/en/documents/variation-report/nordimet-h-c-3983-ii-0027-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Nordimet (II-27)

Adopted

Reference Number: EMA/CHMP/354618/2023

English (EN) (125.51 KB - PDF)

**First published:** 15/09/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nordimet-ii-27_en.pdf)

Nordimet-H-C-3983-II-0016 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/56247/2021

English (EN) (1.2 MB - PDF)

**First published:** 02/02/2021

[View](/en/documents/variation-report/nordimet-h-c-3983-ii-0016-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Nordimet (II-16)

Adopted

Reference Number: EMA/CHMP/658053/2020

English (EN) (122.12 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nordimet-ii-16_en.pdf)

Nordimet-H-C-PSUSA-00002014-201910 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/405544/2020

English (EN) (134.66 KB - PDF)

**First published:** 30/07/2020

[View](/en/documents/scientific-conclusion/nordimet-h-c-psusa-00002014-201910-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Nordimet-H-C-PSUSA-00002014-201810 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/492014/2019

English (EN) (69.8 KB - PDF)

**First published:** 06/09/2019

[View](/en/documents/scientific-conclusion/nordimet-h-c-psusa-00002014-201810-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Nordimet-H-C-PSUSA-00002014-201706 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/357560/2018

English (EN) (67.78 KB - PDF)

**First published:** 15/06/2018

**Last updated:** 15/06/2018

[View](/en/documents/scientific-conclusion/nordimet-h-c-psusa-00002014-201706-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Nordimet : EPAR - Public assessment report

Adopted

Reference Number: EMA/527385/2016

English (EN) (217.86 KB - PDF)

**First published:** 29/09/2016

**Last updated:** 29/09/2016

[View](/en/documents/assessment-report/nordimet-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Nordimet

Adopted

Reference Number: EMA/CHMP/403945/2016

English (EN) (75.13 KB - PDF)

**First published:** 24/06/2016

**Last updated:** 24/06/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-nordimet_en.pdf)

#### News on Nordimet

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0039830000) (initial marketing authorisation)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Nordimet : EPAR - Product information - tracked changes

English (EN) (497.17 KB - DOCX)

**First published:** 17/07/2025

[View](/en/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-689)

български (BG) (696.72 KB - DOCX)

**First published:**

17/07/2025

[View](/bg/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_bg.docx)

español (ES) (498.54 KB - DOCX)

**First published:**

17/07/2025

[View](/es/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_es.docx)

čeština (CS) (578.71 KB - DOCX)

**First published:**

17/07/2025

[View](/cs/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (492.62 KB - DOCX)

**First published:**

17/07/2025

[View](/da/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (563.94 KB - DOCX)

**First published:**

17/07/2025

[View](/de/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (833.77 KB - DOCX)

**First published:**

17/07/2025

[View](/et/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (584.21 KB - DOCX)

**First published:**

17/07/2025

[View](/el/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_el.docx)

français (FR) (488.92 KB - DOCX)

**First published:**

17/07/2025

[View](/fr/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (596.68 KB - DOCX)

**First published:**

17/07/2025

[View](/hr/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (574.55 KB - DOCX)

**First published:**

17/07/2025

[View](/is/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_is.docx)

italiano (IT) (986.5 KB - DOC)

**First published:**

17/07/2025

[View](/it/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (560.16 KB - DOCX)

**First published:**

17/07/2025

[View](/lv/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (641.91 KB - DOCX)

**First published:**

17/07/2025

[View](/lt/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (641.75 KB - DOCX)

**First published:**

17/07/2025

[View](/hu/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (558.19 KB - DOCX)

**First published:**

17/07/2025

[View](/mt/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (561.51 KB - DOCX)

**First published:**

17/07/2025

[View](/nl/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (480.11 KB - DOCX)

**First published:**

17/07/2025

[View](/no/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_no.docx)

polski (PL) (540.08 KB - DOCX)

**First published:**

17/07/2025

[View](/pl/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_pl.docx)

português (PT) (559.67 KB - DOCX)

**First published:**

17/07/2025

[View](/pt/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_pt.docx)

română (RO) (773.48 KB - DOCX)

**First published:**

17/07/2025

[View](/ro/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (743 KB - DOCX)

**First published:**

17/07/2025

[View](/sk/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (615.65 KB - DOCX)

**First published:**

17/07/2025

[View](/sl/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (576.33 KB - DOCX)

**First published:**

17/07/2025

[View](/fi/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (470.03 KB - DOCX)

**First published:**

17/07/2025

[View](/sv/documents/product-information-tracked-changes/nordimet-epar-product-information-tracked-changes_sv.docx)

#### More information on Nordimet

- [Methotrexate containing medicinal products - referral](/en/medicines/human/referrals/methotrexate-containing-medicinal-products)
- [Methotrexate - medication error](/en/medicines/human/medication-error/methotrexate)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/07/2025

## Share this page

[Back to top](#main-content)